Tuesday, 21 April 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 21 April 2026
News

Gilead builds a new revenue play

Posted 21 April 2026 AM

Gilead has continued its push into oncology with a third major acquisition since the start of the year, as it seeks to avoid a repeat of the revenue collapse that followed the successful treatment of hepatitis C.

So far this year Gilead has committed $21.2 billion (US$15 billion) in acquisitions to boost its oncology and immunology portfolios, trying to spread beyond HIV treatments which currently make up around two-thirds of its annual revenues.

To see the whole article, please login

Popular

Drugs jostle for May PBS listing
Leaders pitch for MA Board role
Bosses crack the $40M Club
Gilead builds a new revenue play
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (14)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home